Search

Editorial Feature:

AMD/DME Case Files: Real-World Patient Profiles

Editorially Independent content supported with advertising by Genentech

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Show Description +

How do you approach therapy for a patient whose skepticism of intravitreal injections could lead to her not returning to the clinic? Priya Sharma Vakharia, MD, shares a case which sheds light on how she may approach step therapy—in this case, moving from bevacizumab (Avastin, Genentech) to ranibizumab (Lucentis, Genentech) to aflibercept (Eylea, Regeneron)—and how they decide when switching anti-VEGF agents is appropriate.

Posted: 10/03/2023

Keywords:

Step Therapy

•

Anti-VEGF

•

Intravitreal Injection

•

Season One

Up Next

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Step Therapy Case: A Challenging DME Patient

Real-World Step Therapy Case: A Challenging DME Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Switch Case: Difficult-to-Treat Fluid DME Case Study

Real-World Switch Case: Difficult-to-Treat Fluid DME Case Study

Ferhina Ali, MD

Real-World Step Therapy: Suboptimal Response in Wet AMD

Real-World Step Therapy: Suboptimal Response in Wet AMD

Scott Walter, MD, MSc

Real-World Treatment-Naïve Case: Bilateral Advanced DME Treated with Two Different Agents

Real-World Treatment-Naïve Case: Bilateral Advanced DME Treated with Two Different Agents

Scott Walter, MD, MSc

Switch Case: Potential Response to Ang-2 in Wet AMD

Switch Case: Potential Response to Ang-2 in Wet AMD

Ash Abbey, MD

Switch Case: Faricimab to High-dose Aflibercept

Switch Case: Faricimab to High-dose Aflibercept

Ash Abbey, MD

Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Ferhina Ali, MD; Ash Abbey, MD; and Scott Walter, MD, MSc,

Switch Case: 66-Year-Old Man With Wet AMD

Switch Case: 66-Year-Old Man With Wet AMD

Priya Sharma Vakharia, MD

Potential Switch Case: 81-Year-Old Man With Wet AMD

Potential Switch Case: 81-Year-Old Man With Wet AMD

Priya Sharma Vakharia, MD

Switch Case: Massive PED (Part 1)

Switch Case: Massive PED (Part 1)

Yasha S. Modi, MD

Switch Case: Massive PED (Part 2)

Switch Case: Massive PED (Part 2)

Yasha S. Modi, MD

Switch Case: Bilateral DME and Years of Continuous Anti-VEGF Treatment

Switch Case: Bilateral DME and Years of Continuous Anti-VEGF Treatment

Joseph M. Coney, MD

Treatment-Naïve Case: DME in a 54-Year-Old-Patient With Undiagnosed Diabetes

Treatment-Naïve Case: DME in a 54-Year-Old-Patient With Undiagnosed Diabetes

Joseph M. Coney, MD

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Back to All Videos

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

How do you approach therapy for a patient whose skepticism of intravitreal injections could lead to her not returning to the clinic? Priya Sharma Vakharia, MD, shares a case which sheds light on how she may approach step therapy—in this case, moving from bevacizumab (Avastin, Genentech) to ranibizumab (Lucentis, Genentech) to aflibercept (Eylea, Regeneron)—and how they decide when switching anti-VEGF agents is appropriate.

Posted: 10/03/2023

Keywords:

Step Therapy

•

Anti-VEGF

•

Intravitreal Injection

•

Season One

Please log in to leave a comment.